IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
SETTE *et al.*
Appl. No.: 09/357,737
Filed: July 19, 1999
For: **Inducing Cellular Immune Responses to Hepatitis C Virus Using Peptide and Nucleic Acid Compositions**

Confirmation No.: 9669
Art Unit: 1644
Examiner: Schwadron, R.B.
Atty. Docket: 2060.0030005/PAJ/M-M

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, AA100 to AH100, cited on the attached Form PTO-1449 are not submitted. Copies of all other documents are provided.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The documents cited in this Second Supplemental Information Disclosure Statement are of general relevance to the claimed invention.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: Nov. 29, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

338462_1.DOC

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA100	4,235,877	11/25/1980	Fullerton			06/27/1979
	AB100	4,487,715	12/11/1984	Nitecki *et al.*			07/09/1982
	AC100	4,599,230	07/08/1986	Milich *et al.*			03/09/1984
	AD100	4,837,028	06/06/1989	Allen			12/24/1986
	AE100	5,013,548	05/07/1991	Haynes *et al.*			01/21/1988
	AF100	5,128,319	07/07/1992	Arlinghaus			09/20/1989
	AG100	5,736,142	04/07/1998	Sette *et al.*			09/14/1994
	AH100	5,783,567	07/21/1998	Hedley *et al.*			01/22/1997
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL100	EP 0 378 881	06/09/1993	Europe			Yes No
	AM100	EP 0 429 816	06/05/1991	Europe			Yes No
	AN100	EP 0 433 242	06/19/1991	Europe			Yes No
	AO100	WO 93/03764	03/04/1993	WIPO			Yes No
	AP100	WO 94/20127	09/15/1994	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	100	Alexander, J., *et al.*, "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," *Immunity 1*:751-761, Cell Press (1994)
	AS	100	Arndt, S.O., *et al.*, "Selection of the MHC Class II-Associated Peptide Repertoire by HLA-DM," *Immunol. Res. 16*:261-272, Humana Press (December 1997)
	AT	100	Barouch, D., *et al.*, "HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation," *J. Exp. Med. 182*:1847-1856, Rockefeller University Press (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL101	WO 95/07707	03/23/1995	WIPO			Yes No
	AM101	WO 96/22067	07/25/1996	WIPO			Yes No
	AN101	WO 97/41440	11/06/1997	WIPO			Yes No
	AO101	WO 97/34617	09/25/1997	WIPO			Yes No
	AP101	WO 01/00225	01/04/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	101	Bender, A., *et al.*, "Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood," *J. Immunol. Methods 196*:121-135, Elsevier Science (1996)
	AS	101	Ben-Yedidia, T., and Arnon, R., "Design of peptide and polypeptide vaccines," *Curr. Opin. Biotechnol. 8*:442-448, Current Biology, Ltd. (1997)
	AT	101	Carbone, F.R., and Bevan, M.J., "Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization," *J. Exp. Med. 169*:603-612, Rockefeller University Press (1989)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	102	Carbone, F.R., *et al.*, "Induction of Cytotoxic T Lymphocytes by Primary In Vitro Stimulation with Peptides," *J. Exp. Med. 167*:1767-1779, Rockefeller University Press (1988)
	AS	102	Cassell, D., and Forman, J., "Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes," *Ann. N.Y. Acad. Sci.532*:51-60, New York Academy Of Sciences (1991)
	AT	102	Deres, K., *et al.*, "*In vivo* priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," *Nature 342*:561-564, Nature Publishing Group (1989)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	103	del Guercio, M-F., *et al.*, "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses *in vivo*," *Vaccine 15*:441-448, Elsevier Science (March 1997)
	AS	103	DiBrino, M., *et al.*, "Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," *J. Immunol. 152*:620-631, American Association of Immunologists (1994)
	AT	103	DiBrino, M., *et al.*, "The HLA-B14 Peptide Binding Site Can Accommodate Peptides with Different Combinations of Anchor Residues," *J. Biol. Chem. 269*:32426-32434, American Society for Biochemistry and Molecular Biology (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	104	Donnelly, J.J., *et al.*, "DNA Vaccines," *Annu. Rev. Immunol. 15*:617-648, Annual Reviews Inc. (April 1997)
	AS	104	Francis, M.J., *et al.*, "Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants," *Nature 330*:168-170, Nature Publication Group (1987)
	AT	104	Fynan, E.F., *et al.*, "DNA vaccines: Protective immunizations by parental, mucosal, and gene-gun inoculations," *Proc. Natl. Acad. Sci. USA 90*:11478-11482, National Academy of Sciences (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	105	Gileadi, U., *et al.*, "Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes," *Eur. J. Immunol. 29*:2213-2222, WILEY-VCH Verlag GmbH (July 1999)
	AS	105	Golvano, J., *et al.*, "Polarity of immunogens: implications for vaccine design," *Eur. J. Immunol. 20*:2363-2366, VCH Verlagsgesellschaft mbH (1990)
	AT	105	Gulukota, K., *et al.*, "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," *J. Mol. Biol. 267*:1258-1267, Academic Press Limited (April 1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	106	Hahn, Y.S., *et al.*, "CD8$^+$ T Cell Recognition of an Endogenously Processed Epitope is Regulated Primarily by Residues within the Epitope," *J. Exp. Med. 176*:1335-1341, Rockefeller University Press (1992)
	AS	106	Hahn, Y.S., *et al.*, "Presentation of Viral Antigen to Class I Major Histocompatibility Complex-Restricted Cytotoxic T Lymphocyte. Recognition of an Immunodominant Influenza Hemagglutinin Site by Cytotoxic T Lymphocyte is Independent of the Position of the Site in the Hemagglutinin Translation Product," *J. Exp. Med. 174*:733-736, Rockefeller University Press (1991)
	AT	106	Hammer, J., *et al.*, "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," *J. Exp. Med. 180*:2353-2358, Rockefeller University Press (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	107	Hill, C.M., *et al.*, "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," *J. Immunol. 152*:2890-2898, American Association of Immunologists (1994)
	AS	107	Huczko, E.L., *et al.*, "Characteristics of Endogenous Peptides Eluted from the Class I MHC Molecule HLA-B7 Determined by Mass Spectrometry and Computer Modeling," *J. Immunol. 151*:2572-2587, American Association of Immunologists (1993)
	AT	107	Ishioka, G.Y., *et al.*, "Class I MHC-restricted, peptide specific cytotoxic T lymphocytes generated by peptide priming in vivo," in *Vaccines90: Modern Approaches to New Vaccines Including Prevention of AIDS,* Brown, F., *et al.*, eds., Cold Spring harbor Laboratory Press, Cold Spring Harbor, NY, pp. 7-11 (1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	108	Ishioka, G.Y., *et al.*, "Induction of Class I MHC-Restricted, Peptide-Specific Cytolytic T Lymphocytes by Peptide Priming In Vivo," *J. Immunol. 143*:1094-1100, American Association of Immunologists (1989)
	AS	108	Jardetzky, T.S., *et al.*, "Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding," *EMBO J. 9*:1797-1803, Oxford University Press (1990)
	AT	108	Kast, W.M., *et al.*, "Protection against lethal Sendai virus infection by *in vivo* priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," *Proc. Natl. Acad. Sci. USA 88*:2283-2287, National Academy of Sciences (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	109	Kondo, A., *et al.*, "Two distinct *HLA-A*0101*-specific submotifs illustrate alternative peptide binding modes," *Immunogenetics 45*:249-258, Springer-Verlag (January 1997)
	AS	109	Kubitscheck, U., *et al.*, "Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells," *Scand. J. Immunol. 36*:341-348, Blackwell Scientific Publications (1992)
	AT	109	Kubo, R.T., *et al.*, "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," *J. Immunol. 152*:3913-3924, American Association of Immunologists (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	110	Kumar, A., *et al.*, "Universal T Helper Cell Determinants Enhance Immunogenicity of a *Plasmodium falciparum* Merozoite Surface Antigen Peptide," *J. Immunol. 148*:1499-1505, American Association of Immunologists (1992)
	AS	110	Lasarte, J-J., *et al.*, "Induction of Cytotoxic T Lymphocytes in Mice against the Principal Neutralizing Domain of HIV-1 by Immunization with an Engineered T-Cytotoxic-T-Helper Synthetic Helper Peptide Construct," *Cell. Immunol. 141*:211-218, Academic Press Inc. (1992)
	AT	110	Madden, D.R., *et al.*, "The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation," *Nature 353*:321-325, Nature Publishing Group (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	111	Maier, R., *et al.*, "Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing," *Immunogenetics 40*:306-308, Springer-Verlag (1994)
	AS	111	Martinon, F., *et al.*, "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant," *J. Immunol. 149*:3416-3422, American Association of Immunologists (1992)
	AT	111	Niedermann, G., *et al.*, "Contribution of Proteasome-Mediated Proteolysis to the Hierarchy of Epitopes Presented by Major Histocompatibility Complex Class I Molecules," *Immunity 2*:289-299, Cell Press (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	112	Niedermann, G., *et al.,* "The specificity of proteasomes: impact on MHC class I processing and presentation of antigens," *Immunol. Rev. 172*:29-48, Munksgaard (December 1999)
	AS	112	Nikolić-Žugić, J., and Carbone, F.R., "Peptide Presentation by Class-I Major Histocompatibility Complex Molecules," *Immunol. Res. 10*:54-65, S. Karger AG (1991)
	AT	112	O'Sullivan, D., *et al.,* "Characterization of the Specificity of Peptide Binding to Four DR Haplotypes," *J. Immunol. 145*:1799-1808, American Association of Immunologists (1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	113	O'Sullivan, D., *et al.*, "On the Interaction of Promiscuous Antigenic Peptides with Different DR Alleles," *J. Immunol. 147*:2663-2669, American Association of Immunologists (1991)
	AS	113	Panina-Bordignon, P., *et al.*, "Universally immunogenic T cell eptiopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," *Eur. J. Immunol. 19*:2237-2242, VCH Verlagsgesellschaft mbH (1989)
	AT	113	Paz, P., *et al.*, "Discrete Proteolytic Intermediates in the MHC Class I Antigen Processing Pathway and MHC I-Dependent Peptide Trimming in the ER," *Immunity 11*:241-251, Cell Press (August 1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	114	Penna, A., *et al.,* "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," *J. Exp. Med. 174*:1565-1570, Rockefeller University Press (1991)
	AS	114	Pryjma, J., *et al.,* "Induction and Suppression of Immunoglobulin Synthesis in Cultures of Human Lymphocytes: Effects of Pokeweed Mitogen and *Staphylococcus Aureus* Cowan I," *J. Immunol. 124*:656-661, Williams & Wilkins Co. (1980)
	AT	114	Rahemtulla, A., *et al.,* "Normal development and function of $CD8^+$ cells but markedly decreased helper cell activity in mice lacking CD4," *Nature 353*:180-183, Nature Publishing Group (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	115	Rammensee, H-G., *et al.*, "SYFPEITHI: database for MHC ligands and peptide motifs," *Immunogenetics 50*:213-219, Springer-Verlag (November 1999)
	AS	115	Reitermann, A., *et al.*, "Lipopeptide Derivatives of Bacterial Lipoprotein Constitute Potent Immune Adjuvants Combined with or Covalently Coupled to Antigen or Hapten," *Biol. Chem. Hoppe Seyler 370*:343-352, Walter De Gruyter (1989)
	AT	115	Restifo, N.P., *et al.*, "Antigen Processing In Vivo and the Elicitation of Primary CTL Responses," *J. Immunol. 154*:4414-4422, American Association of Immunologists (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	116	Saper, M.A., *et al.*, "Refined Structure of the Human Histocompatibility Antigen HLA-A2 at 2.6 Å Resolution," *J. Mol. Biol. 219*:277-319, Academic Press Ltd. (1991)
	AS	116	Schaeffer, E.B., *et al.*, "Relative contribution of 'determinant selection' and 'holes in the T-cell repertoire' to T-cell responses," *Proc. Natl. Acad. Sci. USA 86*:4649-4653, National Academy of Sciences (1989)
	AT	116	Schumacher, T.N.M., *et al.*, "Peptide selection by MHC class I molecules," *Nature 350*:703-706, Nature Publishing Group (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	117	Sette, A., and Sidney, J., "HLA supertypes and supermotifs: a functional perspective on HLA polymorphism," *Curr. Opin. Immunol. 10*:478-482, Current Biology Publications (August 1998)
	AS	117	Sette, A., *et al.*, "A Novel Approach to the Generation of High Affinity Class II-Binding Peptides," *J. Immunol. 145*:1809-1813, American Association of Immunologists (1990)
	AT	117	Sette, A., *et al.*, "Effect of Conformational Propensity of Peptide Antigens in Their Interaction with MHC Class II Molecules," *J. Immunol. 143*:1268-1273, American Association of Immunologists (1989)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	118	Sette, A., *et al.*, "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," *Mol. Immunol. 31*:813-822, Pergamon Press (1994)
	AS	118	Sidney, J., *et al.*, "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," *Hum. Immunol. 45*:79-93, Elsevier Science Inc. (1996)
	AT	118	Sidney, J., *et al.*, "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs," *Immunol. Today 17*:261-266, Elsevier Science (1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	119	Sidney, J., *et al.*, "The HLA-A*0207 Peptide Binding Repertoire is Limited to a Subset of the A*0201 Repertoire," *Hum. Immunol. 58*:12-20, Elsevier Science Inc. (November 1997)
	AS	119	Sinigaglia, F., and Hammer, J., "Defining rules for the peptide-MHC class II interaction," *Curr. Opin. Immunol. 6*:52-56, Current Biology Ltd. (1994)
	AT	119	Southwood, S., *et al.*, "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," *J. Immunol. 160*:3363-3373, American Association of Immunologists (April 1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	120	Sprent, J., and Schaefer, M., "Properties of Purified T Cell Subsets. I. In Vitro Responses to Class I vs. Class II H-2 Alloantigens," *J. Exp. Med. 162*:2068-2088, Rockefeller University Press (1985)
	AS	120	Stark, J.M., *et al.*, "Immunogenicity of lipid-conjugated antigens. I. The Influence of Chain Length and Degree of Conjugation on Induction of Antibody in Mice," *Immunology 39*:345-352, Blackwell Scientific Publications (1980)
	AT	120	Steinman, R.M., "Dendritic cells and immune-based therapies," *Exp. Hematol. 24*:859-862, Elsevier Science Inc. (1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	121	Sudo, T., *et al.*, "Differences in MHC Class I Self Peptide Repertoires Among HLA-A2 Subtypes," *J. Immunol. 155*:4749-4756, American Association of Immunologists (1995)
	AS	121	Sugawara, S., *et al.*, "A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3," *J. Immunol. Methods 100*:83-90, Elsevier Science (1987)
	AT	121	Tam, J.P., and Lu, Y-A., "Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes," *Proc. Natl. Acad. Sci. USA 86*:9084-9088, National Academy of Sciences (1989)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	122	Townsend, A., and Bodmer, H., "Antigen Recognition by Class I-Restricted T Lymphocytes," *Ann. Rev. Immunol. 7*:601-624, Annual Reviews, Inc. (1989)
	AS	122	von Boehmer, H., and Haas, W., "Distinct Ir Genes for Helper and Killer Cells in the Cytotoxic Response to H-Y Antigen," *J. Exp. Med. 150*:1134-1142, Rockefeller University Press (1979)
	AT	122	Watari, E., *et al.*, "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," *J. Exp. Med. 165*:459-470, Rockefeller University Press (1987)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	123	Wentworth, P.A., *et al.*, "*In Vitro* Induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," *Mol. Immunol. 32*:603-612, Elsevier Science Ltd. (1995)
	AS	123	Wherry, E.J., *et al.*, "The Induction of Virus-Specific CTL as a Function of Increasing Epitope Expression: Responses Rise Steadily Until Excessively High Levels of Epitope Are Attained," *J. Immunol. 163*:3735-3745, American Association of Immunologists (October 1999)
	AT	123	Widmann, C., *et al.*, "T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides," *J. Immunol. Meth. 155*:95-99, Elsevier Science Publishers B.V. (1992)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	124	Wiesmüller, K-H., *et al.*, "Lipopeptide-Helper-T-Cell Epitope-CTL Epitope Conjugate Induces Antibodies Against the CTL Epitope," *Innovation Perspective Solid Phase Synthesis Collect. Papers, Int. Symp. 2nd*, pp. 499-502 (1991)
	AS	124	Wiesmüller, K-H., *et al.*, "Novel low-molecular-weight synthetic vaccine against foot-and mouth disease containing a potent B cell and macrophage activator," *Vaccine* 7:29-33, Butterworth & Co. (1989)
	AT	124	Yewdell, J.W., and Bennink, J.R., "Immunodominance in Major Histocompatibility Complex Class I-Restricted T Lymphocyte Responses," *Annu. Rev. Immunol. 17*:51-88, Annual Reviews Inc. (April 1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0030005	APPLICATION NO. 09/357,737
	APPLICANT(S) SETTE *et al.*	
	FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	125	Zhou, X., *et al.*, "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides," *J. Immunol. Methods 153*:193-200, Elsevier Science Publishers B.V. (1992)
	AS	125	Zinkernagel, R.M., *et al.*, "The Lymphoreticular System in Triggering Virus Plus Self-Specific Cytotoxic T Cells: Evidence for T Help," *J. Exp. Med. 147*:897-911, Rockefeller University Press (1978)
	AT		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 9669
SETTE *et al.*	Art Unit: 1644
Appl. No.: 09/357,737	Examiner: Schwadron, R.B.
Filed: July 19, 1999	Atty. Docket: 2060.0030005/PAJ/M-M
For: **Inducing Cellular Immune Responses to Hepatitis C Virus Using Peptide and Nucleic Acid Compositions**	

Third Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, AA200 to AB200, cited on the attached Form PTO-1449 are not submitted. Copies of all other documents are provided.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The documents cited in this Third Supplemental Information Disclosure Statement generally relate to HCV peptides.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: Nov. 29, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

338480_1.DOC

FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2060.0030005	09/357,737
APPLICANT(S)	
SETTE *et al.*	
FILING DATE	ART UNIT
July 19, 1999	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA200	5,980,899	11/09/1999	Berzofsky *et al.*			06/10/1992
	AB200	6,150,087	11/21/2000	Chien			05/18/1995
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL200	WO 95/25122	09/21/1995	WIPO			Yes No
	AM200	WO 97/34621	09/25/1997	WIPO			Yes No
	AN200	EP 0 318 216 B1	05/31/1989	Europe			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	200	Cerny, A., *et al.*, "Induction *in vitro* of a primary human antiviral cytotoxic T cell response," *Eur. J. Immunol. 25*:627-630, VCH Verlagsgesellschaft (1995)
	AS	200	Chang, K-M., *et al.*, "Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis C Virus in Patients with Acute and Chronic Hepatitis C," *J. Immunol. 162*:1156-1164, American Association of Immunologists (January 1999)
	AT	200	Kita, H., *et al.*, "HLA B44-Restricted CTL Response to HCV Nucleocapsid Protein Derived Peptides from Different HCV Isolates," *Hepatology AASLD Abstract No. 631*:214A, Williams & Wilkins (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2060.0030005	09/357,737
APPLICANT(S)	
SETTE *et al.*	
FILING DATE	ART UNIT
July 19, 1999	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	201	Koziel, M.J., *et al.*, "Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV," *J. Virol. 67*:7522-7532, American Society For Microbiology (1993)
	AS	201	Lamonaca, V., *et al.*, "Conserved Hepatitis C Virus Sequences are Highly Immunogenic for $CD4^+$ T Cells: Implications for Vaccine Development," *Hepatology 30*:1088-1098, Williams & Wilkins (October 1999)
	AT	201	Oseroff, C., *et al.*, "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses," *Vaccine 16*:823-833, Elsevier Science (April 1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2060.0030005	09/357,737
APPLICANT(S)	
SETTE *et al.*	
FILING DATE	ART UNIT
July 19, 1999	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	202	Rammensee, H-G., *et al.*, "MHC ligands and peptide motifs: first listing," *Immunogen. 41*:178-228, Springer-Verlag (1995)
	AS	202	Sarobe, P., *et al.*, "Enhanced In Vitro Potency and In Vivo Immunogenicity of a CTL Epitope from Hepatitis C Virus Core Protein following Amino Acid Replacement at Secondary HLA-A2.1 Binding Positions," *J. Clin. Invest. 102*:1239-1248, American Society for Clinical Investigation (September 1998)
	AT	202	Schulz, M., *et al.*, "Peptide-induced antiviral protection by cytotoxic T cells," *Proc. Natl. Acad. Sci. USA 88*:991-993, National Academy of Sciences (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2060.0030005	09/357,737
APPLICANT(S) SETTE *et al.*	
FILING DATE July 19, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	203	Shirai, M., *et al.*, "Use of Intrinsic and Extrinsic Helper Epitopes for In Vivo Induction of Anti-Hepatitis C Virus Cytotoxic T Lymphocytes (CTL) with CTL Epitope Peptide Vaccines," *J. Infect. Dis. 173*:24-31, University of Chicago Press (1996)
	AS	203	Wentworth, P.A., *et al.*, "Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome," *Int. Immunol. 8*:651-659, Oxford University Press (1996)
	AT		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.